Additionally, they have an effect in reducing Lp(a), unlike statins, which also contributes to their beneficial effects regarding CV morbidity and mortality, which have been proven in studies such as ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) with alirocumab and FOURIER (the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) with evolocumab [42,43,44]. The gene discussed is PCSK9; the disease is acute coronary syndrome.